Genetic diversity of Mycobacterium tuberculosis strains circulating in Botswana by Mogashoa, Tuelo et al.
RESEARCH ARTICLE
Genetic diversity of Mycobacterium
tuberculosis strains circulating in Botswana
Tuelo MogashoaID1,2, Pinkie Melamu2, Serej D. Ley3,4, Elizabeth M. Streicher3,
Thato IketlengID2,5, Nametso Kelentse2, Lucy Mupfumi1,2, Margaret Mokomane6,
Botshelo Kgwaadira6, Vladimir Novitsky2,7, Ishmael Kasvosve1, Sikhulile Moyo2,7, Robin
M. Warren3, Simani Gaseitsiwe2,7*
1 Department of Medical Laboratory Sciences, Faculty of Health Sciences, University of Botswana,
Gaborone, Botswana, 2 Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana, 3 DST-NRF
Centre of Excellence in Biomedical Tuberculosis Research, South African Medical Research Council Centre
for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and
Health Sciences, Stellenbosch University, Cape Town, South Africa, 4 Swiss Tropical and Public Health
Institute, Basel, Switzerland, 5 College of Health Sciences, School of Laboratory Medicine and Medical
Sciences, University of KwaZulu-Natal, Durban, South Africa, 6 National Tuberculosis Reference Laboratory,
Ministry of Health and Wellness, Gaborone, Botswana, 7 Harvard T.H. Chan School of Public Health, Boston,
Massachusetts, United States of America
* sgaseitsiwe@gmail.com, sgaseitsiwe@bhp.org.bw
Abstract
Background
Molecular typing of Mycobacterium tuberculosis (M.tb) isolates can inform Tuberculosis
(TB) control programs on the relative proportion of transmission driving the TB epidemic.
There is limited data on the M. tb genotypes that are circulating in Botswana. The aim of this
study was to generate baseline data on the genetic diversity of M.tb isolates circulating in
the country.
Methods
A total of 461 M.tb isolates received at the Botswana National Tuberculosis Reference Lab-
oratory between March 2012 and October 2013 were included in this study. Drug suscepti-
bility testing was conducted using the BD BACTEC MGIT 960 System. M.tb strains were
genotyped using spoligotyping and spoligotype patterns were compared with existing pat-
terns in the SITVIT Web database. A subset of drug resistant isolates which formed spoligo
clusters (n = 65) was additionally genotyped with 12-loci MIRU. Factors associated with
drug resistance and clustering were evaluated using logistic regression.
Results
Of the 461 isolates genotyped, 458 showed 108 distinct spoligotype patterns. The predomi-
nant M.tb lineages were Lineage 4 (81.9%), Lineage 2 (9%) and Lineage 1 (7.2%). The pre-
dominant spoligotype families within Lineage 4 were LAM (33%), S (14%), T (16%), X
(16%). Three hundred and ninety-two (86%) isolates could be grouped into 44 clusters (2–
46 isolates per cluster); giving a clustering rate of 76%. We identified 173 (37.8%) drug
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resistant isolates, 48 (10.5%) of these were multi-drug resistant. MIRU typing of the drug
resistant isolates allowed grouping of 46 isolates into 14 clusters, giving a clustering rate of
49.2%. There was no association between age, sex, treatment category, region and
clustering.
Conclusions
This study highlights the complexity of the TB epidemic in Botswana with multiple strains
contributing to disease and provides baseline data on the population structure of M.tb
strains in Botswana.
Introduction
Tuberculosis (TB) is amongst the top 10 causes of death throughout the world [1]. In 2017, an
estimated 10.4 million people fell ill with TB; an estimated 1.3 million HIV uninfected people
and 374 000 HIV infected people died of the disease. Botswana is a high TB burden country
with an estimated TB incidence rate of 300 per 100,000 population [2]. According to the 2014
National TB report, about 60% of TB patients in Botswana are also co-infected with HIV [3].
Despite this high TB burden, studies to identify drivers of the TB epidemic in Botswana are
sparse. The genetic diversity of Mycobacterium tuberculosis (M.tb) strains in Botswana remains
largely unknown.
Molecular typing of M.tb is a useful tool to better understand the epidemiology of TB [4, 5].
Spacer oligonucleotide typing (spoligotyping), a genotyping method based on the amplifica-
tion of the direct repeat (DR) region of the M.tb genome, is a rapid method to detect and dif-
ferentiate M.tb clinical specimens into different lineages and sub-lineages [6, 7]. Mycobacterial
Interspersed Repetitive Units—Variable Number of Tandem Repeats (MIRU-VNTR) is
another polymerase chain reaction (PCR) based genotyping method used to differentiate M.tb
strains[8]. Both, spoligotyping and MIRU-VNTR typing methods are widely used and results
of these assays are stored in international databases [9, 10]. Another genotyping method,
which has been proven useful in investigating TB transmission in the past, is the insertion
sequence 6110 restriction fragment length polymorphism (IS6110-RFLP) typing [5, 11–14].
These assays enable the study of the global distribution and phylogenetic analyses of M.tb line-
ages across countries. M.tb lineages have been found to be distributed differently across the
globe and thus reflect migration patterns and local epidemiology[15]. Tracking recent trans-
mission chains in a TB endemic area enables the TB control programs to identify transmission
hotspots and to implement effective targeted interventions [16].
Monitoring circulating M.tb strains remains a critical part of any TB control program as it
can help improve our understanding of transmission dynamics in specific geographical loca-
tions [17]. Studies were previously conducted in Botswana by Lockman et al. to investigate the
molecular epidemiology of M.tb. The findings of these studies in four communities and the
population at large showed that there was IS6110-RFLP clustering rate of 25% and 38% respec-
tively [18, 19]. The high IS6110-RFLP clustering rates were suggestive of active transmission
within communities in Botswana. However, the studies conducted by Lockman et al. did not
provide any detailed information on the phylogenetic lineages of the M.tb strains that were
genotyped. Importantly, these studies were carried out more than 18 years ago so there is a
need to generate more recent data on the M.tb diversity in Botswana. We generated more
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recent baseline data on the genetic diversity and distribution of circulating M.tb strains from
specimens collected throughout Botswana.
Methods
Study setting and population
This was a retrospective, cross-sectional study. The study was approved by the University of
Botswana Ethics Institutional Review Board and the Ministry of Health and Wellness Human
Research Development Division. Permission was granted to use de-identified patient clinical
information therefore patient consent was waived [Reference No: HPDME: 13/18/1 Vol. XI
(140)]. We obtained all M.tb isolates (n = 461) that were available from the Botswana National
Tuberculosis Reference Laboratory (NTRL) bio-repository. NTRL is a reference laboratory
that receives sputum specimens for microscopy, culture and drug susceptibility testing (DST)
from all public health facilities throughout the country. M.tb isolates included in this study
were obtained from pulmonary and extrapulmonary samples received at NTRL from March
2012 to October 2013. These specimens were collected from 146 regional health posts, clinics
and hospitals across all the 24 health districts and later sent to NTRL for culture. At the time of
the study the indications for culture were as follows: HIV positive patients with 2 negative spu-
tum smear results, new patients who are smear positive at month 3 of treatment, all retreat-
ment patients, patients who have received anti-tuberculosis therapy (ATT) for more than 1
month in the past, all children, patients who develop TB during or after isoniazid preventative
(IPT), symptomatic individuals who are at higher risk of MDR-TB such as health care workers,
MDR-TB contacts and laboratory personnel, patients with suspected cryptogenic TB as well as
fluids or tissues which are suspected to be infected by M.tb[3]. The patients’ clinical informa-
tion was obtained from the laboratory patient management system.
The administrative health districts were grouped into 4 regions namely; North West, Cen-
tral, Southern and South West. A central location was chosen for each region and its coordi-
nates were used to plot the distribution of lineages in each region. The Botswana map was
generated by using freely available R packages ggmap, maps and mapdata. The maps with pie
charts were edited using Adobe Illustrator CS6. The get_map() is a smart wrapper that queries
Stamen Maps by specified longitude (19.8, 29) and latitude (-18, -26.7).
Drug susceptibility testing
Drug susceptibility testing (DST) for the first line drugs; isoniazid (INH), rifampicin (RIF),
ethambutol (EMB) and streptomycin (STR) was performed using the BACTEC MGIT 960 Sys-
tem (Becton Dickinson Diagnostic Systems, Sparks, MD, USA) following the manufacturer’s
instructions. Susceptibility to first line drugs was tested at the following concentrations: 0.1 μg/
mL and 0.4 μg/mL for low and high concentrations of isoniazid respectively, 1.0 μg/mL for
rifampicin and streptomycin and 5.0 μg/mL for ethambutol. Isolates were categorized into
groups based on the resistance profile. Resistance to only one drug was termed monoresis-
tance, resistance to at least isoniazid (INH) and rifampicin (RIF) were termed multi-drug resis-
tance (MDR) and resistance to more than one first line drug but not meeting MDR criteria
was termed polyresistance.
DNA extraction
DNA was extracted from the BD MGIT cultures (BD Biosciences, Sparks, MD, USA) using the
GenoLyse DNA extraction kit version 1.0 (Hain LifeScience, GmBH, Nehren, Germany) fol-
lowing the manufacturer’s instructions.
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Spoligotyping
Spoligotyping was performed as previously described by Kamerbeek et al. [6] on 461 isolates.
A commercially available spoligotyping kit (Mapmygenome, Hyderabad India) was used for
amplification, hybridization and detection of DNA. The direct repeat (DR) region of the iso-
lates was amplified by PCR using oligonucleotides primers DRa (5’-GGTTTTGGGTCTGAC
GAC-3’) biotinylated at the 5’ end) and DRb (5’-CCGAGAGGGGACGGAAAC-3’) derived
from the DR sequence for 30 cycles at a Tm of 55˚C. The characterized M.tb strains H37Rv
(laboratory reference strain) and Mycobacterium bovis (M.bovis)- Bacillus Calmette-Gue´rin
(BCG) were included as positive controls; distilled water with PCR mix was used as negative
control in each run. The resulting spoligotype patterns were reported in octal and binary for-
mats and compared to existing patterns in the international genotyping database SITVIT2 [10]
available at the following address: http://www.pasteur-guadeloupe.fr:8081/SITVIT_ONLINE/.
Spoligotype patterns were grouped as spoligotype international types (SITs) if they shared
identical patterns with existing patterns in the database. Isolates that did not share their pat-
terns with previously reported patterns were termed “unknown”. M.tb lineages and families
were assigned based on spoligotyping data submitted to the SITVIT2 database. A clustering
rate for spoligotyping was calculated using the formula (nc−c)/n, where nc is the total number
of isolates clustered by spoligotyping, c is the number of clusters and n is the total number of
isolates that were genotyped. A cluster was defined as two or more isolates with identical spoli-
gotype patterns.
MIRU typing
To enhance the discriminatory resolution to identify possible clusters of transmission we
applied the standardized 12-loci MIRU-VNTR protocol by Supply et al. [20] to the subset of
isolates that were resistant to either INH or RIF or to both INH and RIF and which clustered
according to spoligotyping (n = 65). M.tb H37Rv DNA was used as positive control and
DNA-free water as a negative control. The PCR products were fractionated by electrophoresis
in 2% agarose gels in 1XTris/Borate/Ethylenediaminetetraacetic acid buffer (TBE buffer)
at 65V for 16hrs to allow for clear discrimination. The number of repeats at each locus was cal-
culated from the size of DNA fragments according to the standardized table (http://www.
MIRU-VNTRplus.org). The results were recorded in a digital format where each digit repre-
sented the number of repeats at a particular locus. A clustering rate for MIRU was calculated
using the formula (nc−c)/n, where nc is the total number of isolates clustered by MIRU, c is
the number of clusters and n is the total number of MIRU typed isolates in the study. A cluster
was defined as two or more isolates with identical MIRU patterns.
Data analysis
STATA version 14 (Stata Corp, College Station, TX, USA) was used for statistical analysis. Fac-
tors associated with drug resistance and clustering were evaluated using univariate logistic
regression. A p-value of<0.05 was considered statistically significant.
Results
A total of 458/461 isolates were successfully spoligotyped. Of these 458 isolates, 174 (38%)
were from the Central region, 222 (48.5%) Southern, 34 (7.4%) South West and 28 (6.1%) were
from the North West region (Fig 1). The TB patients had a median age of 36 [IQR 27–44],
with most of them (47%) falling in the age group 20–39 years. Treatment category I (new
cases) made up the largest proportion of our cases (43%) compared to retreatment and MDR
Genetic diversity of Mycobacterium tuberculosis strains in Botswana
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categories. Among the 334 TB patients whose HIV status was known, 239 (72%) were HIV
positive, 95 (28%) HIV negative (Table 1).
Based on the phenotypic DST results, 268 isolates (58.5%) were susceptible to all four first
line drugs while 173 isolates (37.8%) were resistant to at least one drug, 17 isolates (3.7%) did
not have DST results. Among isolates with drug resistance, 111 (24.2%) were monoresistant,
48 (10.5%) were MDR while 14 (3.1%) were polyresistant (Table 2). Out of 173 patients whose
isolates were resistant to at least one drug, 54% were males, 52% were HIV positive (127
patients had a known HIV status), 54% belonged to the 20–39 age group.
The M.tb lineages identified in our dataset belonged to Lineage 4 (Euro American) (81.9%),
Lineage 2 (East Asian) (9.0%), Lineage 1 (Indo-Oceanic) (7.2%), and Lineage 3 (East-African-
Indian) (0.4%).Five isolates (1.1%) could not be assigned to any of the known lineages. Within the
Lineage 4 strains, spoligo families included Latin American Mediterranean (LAM) (32.8%) fol-
lowed by X (16.4%), T (15.9%), S (13.5%), Haarlem (4.6%), U (0.7%) and H37Rv (0.4%). All Line-
age 2 strains belonged to the Beijing family. Lineage 1 strains included the EAI (6.8%) and MANU
(0.4%) families whereas Lineage 3 strains included the CAS family (0.4%). Only one case of M.
bovis (0.2%) and one case of AFRI_1 (M. africanum, Lineage 6) (0.2%) were detected (Table 3).
We identified 108 distinct spoligotype patterns; 44 clusters (2–46 isolates per cluster) and
69 had unique spoligotype patterns (S1 Table). The clustering rate for spoligotyping was found
to be 76%. Lineage 4 (Euro American) was also the most prevalent lineage within the drug
resistant TB isolates (81%) (Table 4). Sixty-five of the 173 drug resistant isolates were success-
fully genotyped by MIRU. We identified 33 MIRU patterns among the drug resistant isolates;
46 isolates formed 14 clusters (2–6 isolates per cluster) and 19 isolates had unique MIRU pat-
terns. The MIRU clustering rate for a subset of drug resistant isolates was calculated to be
49.2% (S2 Table). Using univariate logistic regression analysis there was no association
between age, sex, HIV status, treatment category or geographical region and clustering
(Table 4). The risk of resistance to at least one anti-TB drug was 1.4 (p = 0.067) and 1.1
(p = 0.676) times higher for females and HIV negative patients respectively, but this was not
statistically significant. We also could not detect an association between sex, age, HIV status,
M.tb lineage and drug resistance (Table 5)
Fig 1. Geographical distribution of M.tb lineages and drug resistance profiles in Botswana. A map of Botswana is shown in which pie charts indicate (A) the M.tb
lineages (see key). On the right map (B) the pie charts indicate the drug resistance profiles of the isolates (see key). The size of the pie chart is proportional to the number
of isolates in the region.
https://doi.org/10.1371/journal.pone.0216306.g001
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Discussion
This study provides most recent insights on the genetic diversity of M.tb strains circulating in
Botswana. The analyzed M.tb strains belong to Lineages 1–4 and 6 with a predominance of
Lineage 4 strains. Within Lineage 4 strains, the predominant families were LAM (Latin Ameri-
can Mediterranean), S, T and X. Previous studies have shown that the TB epidemic in Africa is
dominated by Lineage 4 (Euro-American) strains [21]. In Southern Africa LAM11-ZWE and
Lineage 2 (East Asian) have been shown to be dominant [21].
The overall strain diversity observed in Botswana is similar to that of M.tb lineages in neigh-
boring countries South Africa, Zambia and Zimbabwe [21–23]. The presence of the AFRI_1
(Lineage 6) strain in the central region of Botswana is noteworthy. This M.tb family is usually
not found outside of West African countries [24–26]. In a recent study by Mbugi et al to assess
Table 1. Baseline demographics of the patients in the study.
Characteristic n = 458
n %
Sex (n = 454)
Male 232 50.7
Female 225 49.1
Unknown 1 0.2
Age, median [IQR] 36, [44–27]
<20 years 55 12.9
20–39 years 214 46.7
40–59 years 124 27.1
>60 years 33 7.2
Unknown 32 7.0
HIV status
Positive 239 52.2
Negative 95 20.7
Unknown 124 27.1
Specimen type
Extra-pulmonary 38 8.3
Pulmonary 415 90.6
Unknown 5 1.1
Smear result
Smear negative 123 26.9
Smear positive 335 73.1
Treatment category at baseline
Category I� 196 42.7
Category II�� 109 23.7
Multi drug resistant TB (MDR) 23 5.0
Unknown 130 28.4
Region
Central 174 38.0
South West 34 7.4
North West 28 6.1
Southern 222 48.5
� Category 1: This includes new cases, contacts and children
��Category 2: This includes retreatment cases, relapse cases
https://doi.org/10.1371/journal.pone.0216306.t001
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Table 2. Phenotypic drug resistance profiles and lineages of the M.tb isolates in the study.
Drug resistance profile 1 Lineage 1 Lineage 2 Lineage 4 Other^ Total
(n = 33) n (%) (n = 41) n (%) (n = 375) n (%) (n = 9) n (%) (n = 458)
n (%)
#Monoresistant - 1 (2.4) 110 (29.3) - 111 (24.2)
INH - 1(2.4) 5 (1.3) - 6 (1.3)
RIF - - 12 (3.2) - 12 (2.6)
STR - - 91(24.3) - 91 (19.9)
EMB - - 2 (0.5) - 2 (0.4)
��Polyresistant 1 (3.0) - 13 (3.5) - 14 (3.1)
INH + STR - - 7 (1.9) - 7 (1.5)
INH +EMB - - 3 (0.8) - 3 (0.7)
INH + STR + EMB 1 (3.0) - 1 (0.3) - 2 (0.4)
STR +EMB - - 2 (0.5) - 2 (0.4)
���MDR 9 (27.2) 13 (31.7) 25 (6.7) 1 (11.1) 48 (10.5)
INH + RIF - 5 (12.2) 5 (1.3) - 10 (2.2)
INH + RIF + EMB 1 (3.0) 3 (7.3) 6 (1.6) - 10 (2.2)
INH + RIF + STR - 1 (2.4) 2 (0.5) - 3 (0.7)
INH + RIF + STR + EMB 8 (24.2) 4 (9.8) 12 (3.2) 1 (11.1) 25 (5.5)
Pan-susceptible 21 (63.6) 23 (56.1) 217 (57.9) 7 (77.8) 268 (58.5)
No DST result� 2 (6.1) 4 (9.8) 10 (2.7) 1 (11.1) 17 (3.7)
Drug resistance profile
1: INH- Isoniazid, RIF- rifampicin, STR- streptomycin, EMB- Ethambutol
#Monoresistant: resistant for one of the drugs: INH, EMB, RIF, STR
��Polyresistant: resistance to more than one first-line anti-TB drug, other than both INH and RIF (drug-resistant tuberculosis other than MDR-TB)
���MDR: Multi-drug resistance (resistance to at least both isoniazid and rifampicin
^Other includes isolates from an unknown Lineage
�First line DST was not done for these isolates
https://doi.org/10.1371/journal.pone.0216306.t002
Table 3. Proportion of M. tuberculosis lineages and Spoligotype defined families (n = 458).
Lineage Family n (%)
Lineage 1 (Indo-Oceanic) 33 (7.2)
EAI 31 (6.8)
MANU 2 (0.4)
Lineage 2 (East-Asian) Beijing 41 (9.0)
Lineage 3 (East-African-Indian) CAS 2 (0.4)
Lineage 4 (Euro-American) 375 (81.9)
LAM 150 (32.8)
Haarlem 21 (4.6)
H37Rv 2 (0.4)
S 62 (13.5)
T 73 (15.9)
U 3 (0.7)
X 75 (16.4)
Lineage 6 (West African 2) AFRI_1 1 (0.2)
Animal strains (Bovis) Bovis2 1 (0.2)
Unknown Unknown 5 (1.1)
https://doi.org/10.1371/journal.pone.0216306.t003
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the genetic diversity of M.tb in Africa, countries that share borders with Botswana such as
South Africa, Namibia, Zambia and Zimbabwe did not report any Lineage 6 strains. Lineage 6
strains were only reported in Cameroon, Nigeria and Sudan which is consistent with other
published data [22]. The Lineage 6 M.tb strain detected in our study could have been intro-
duced through recent human migrations between West African countries and Botswana.
However, since no additional clinical or ethnicity data from the respective patient was avail-
able, we can only speculate about the origin of the strain and more investigations are required
to assert this hypothesis.
An interesting finding in this study is the presence of an M. bovis strain–the causative agent
of bovine tuberculosis (BTB) [23, 27]. The presence of only one animal strain in our dataset
suggests that there is either a low burden of BTB among cattle or low transmission rates from
cattle to humans. There is limited data on the prevalence of BTB in Botswana and in one study
carried out in the Northern region of Botswana by Jori et al. in 2013 the prevalence of BTB was
reported to be very low [27]. The impact of BTB as a zoonotic disease in Botswana remains to
a greater extent unknown and warrants further studies. There were 2 (0.4%) isolates with a
genotype of the reference strain H37Rv; reasons for this might be laboratory contamination of
patient samples with the reference strain. This however could not be further investigated.
There is limited published data about M.tb genotype clustering rates in African countries.
The clustering rate obtained in this study by spoligotyping was 76% and comparable with
those previously reported by Mulenga et al. in a study at Ndola district in Zambia [13]. A pre-
vious study in Botswana by Lockman et al., obtained a population clustering rate of 38% by
IS6110 RFLP [18]. This clustering rate was much lower than that obtained by spoligotyping,
which is to be expected since IS6110 RFLP is a more discriminatory genotyping method. The
clustering rate for a subset of drug resistant isolates was 49.2%. These results cannot be used to
Table 4. Univariate logistic regression analysis for the odds of clustering.
Characteristic clustered isolates (n = 389) unique isolates (n = 69) OR (95%CI) p values
Age n, (%)
<20 years� 47 (2.9) 8 (12.7)
20–39 years 180 (49.6) 34 (54.0) 0.90 (0.39,2.08) 0.81
40–59 years 106 (29.2) 18 (28.6) 1.00 (0.41,2.47) 0.99
>60 years 30 (8.3) 3 (4.8) 1.70 (0.42,6.93) 0.46
Sex
Female� 200 (51.4) 32 (46.4)
Male 189 (48.6) 36 (52.2) 1.19 (0.71,1.99) 0.51
Treatment category
Category I� 165 (42.4) 31 (44.9)
Category II 97 (24.9) 12 (17.4) 1.52 (0.75,3.10) 0.25
MDR 22 (5.7) 1 (1.45) 4.13 (0.54,31.8) 0.17
HIV status
Negative� 78 (20.1) 17 (24.6)
Positive 204 (52.4) 35 (50.7) 1.27 (0.67,2.40) 0.46
Region
Central� 152 (39.0) 22 (31.9)
North West 22 (5.7) 6 (8.7) 0.53 (0.19,1.45) 0.22
South West 26 (6.7) 8 (11.6) 0.47 (0.19,1.17) 0.10
Southern 189 (48.6) 33 (47.8) 0.83 (0.46,1.48) 0.53
�Reference category.
https://doi.org/10.1371/journal.pone.0216306.t004
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infer transmission since 12 loci MIRU is not discriminatory enough to identify possible trans-
mission chains [16]. Compared to other studies conducted in Zambia and Benin showing
MIRU clustering rates of 37.7% and 34% respectively, our clustering rate is higher than those
obtained in both countries [13]. Further investigations on the transmission dynamics in
Botswana through the use of highly discriminatory genotyping techniques such as whole
genome sequencing are required to determine the proportion of clustered (i.e. transmitted)
versus non-clustered (i.e. acquired/imported/reactivated) drug resistant TB cases. The pres-
ence of unclustered or unique isolates suggests that TB reactivation and/or individual cases of
imported TB from neighbouring countries may be playing a role in local TB epidemiology
[28]. Since the unclustered isolates are acquired or reactivated, diagnosis or treatment compli-
ance could be a problem and may need to be investigated.
According to the previous national anti-tuberculosis drug resistance survey conducted
between 2003 to 2013, there has been an increase in cases of drug resistant TB in Botswana; the
proportion of new patients with any resistance to INH and RIF had increased 3.1-fold since
Table 5. Logistic regression for factors associated with drug resistance.
Pan-susceptible
n (%)
Any drug resistance
n (%)
Association with resistance to at least 1 drug
Variable OR (95%CI) p value
Sex
Male� 144 (53.7) 78 (45.1)
Female 121 (45.2) 94 (54.3) 1.434 (0.976–2.108) 0.067
Age
<20 years� 25 (10.1) 25 (15.5)
20–39 years 133 (53.6) 78 (48.5) 0.586 (0.315–1.091) 0.092
40–59 years 70 (28.3) 48 (29.8) 0.686 (0.352–1.333) 0.266
>60 years 20 (8.1) 10 (6.2) 0.500 (0.195–1.280) 0.148
Region
Central� 98 (36.6) 69 (39.8)
South West 20 (7.5) 13 (7.5) 0.923 (0.430–1.980) 0.837
North West 15 (5.6) 10 (5.8) 0.947 (0.402–2.232) 0.901
Southern 135 (50.4) 81 (46.8) 0.852 (0.564–1.288) 0.448
HIV Status
Positive� 141 (52.6) 91 (52.6)
Negative 53 (19.8) 38 (22) 1.111 (0.676–1.819) 0.676
Smear result
Positive� 196 (73.1) 133 (76.9)
Negative 72 (26.9) 40 (23.1) 0.819 (0.525–1.277) 0.378
Lineage
Lineage 2� 23 (8.6) 14 (8.1)
Lineage 3 21 (7.8) 10 (5.8) 0.782 (0.286–2.136) 0.632
Lineage 4 217 (81) 148 (85.6) 1.120 (0.558–2.248) 0.749
Other# 7 (2.6) 1 (0.6) 0.235 (0.026–2.114) 0.196
� Reference category
# Other includes M.tb isolates which belong to Lineage 3, Lineage 6, Bovis (animal strains), Unknown
OR = Odds ratio
CI = Confidence interval
n = 441, 17 isolates excluded from analysis because they did not have DST result
https://doi.org/10.1371/journal.pone.0216306.t005
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2002. In the TB drug resistance survey conducted between 20017 and 2008, 82 out of the 924
(8.9%) isolates which were included in the survey were resistant to either INH, RIF or EMB
[29]. Among new patients (n = 70) 7.6% were resistant against INH, (33) 3.6% were resistant
against RIF, (17) 1.8% were resistant against EMB and (96) 10.6% were resistant against strep-
tomycin [30]. In this study, there were 196 (43%) new TB cases. Almost 40% of the isolates
were resistant to at least one first line anti-TB drug, with monoresistance detected mainly to
streptomycin (19.9%) and rifampicin (2.6%). This however, does not reflect the drug resistance
rates in the general population due to the national TB program’s criteria for culturing speci-
mens at the time of the study. The high rates of streptomycin resistance could be attributed to
the fact that streptomycin was at the time of the study used in empiric retreatment regimens
before drug resistance testing results are available, it is also commonly used to treat other bac-
terial infections [29, 31]. The presence of both INH and RIF monoresistance indicates that
there is an increased risk for development of MDR-TB especially in cases where patients are
not properly adhering to treatment [32, 33]. There were no significant associations between
drug resistance and sex, age, lineage or smear result in this study. Similar findings have been
reported in other countries [34].
We acknowledge that our study had some limitations. Firstly, there is a selection bias in the
study population because cultures were only performed for a certain group of patients who
met the national culture inclusion criteria as described in the methods section. As a result, our
findings may not be generalizable to the entire population. Secondly, the use of spoligotyping
and 12-loci MIRU typing does not allow to draw conclusions about recent transmission of M.
tb in Botswana. 15 loci or 24 loci-MIRU-VNTR typing methods with an automated system
could potentially already reduce cluster rates, but despite having frequently been used for
transmission analyses, a recent study by Meehan et al. showed that MIRU-typing generally is
not discriminatory enough for that purpose [16]. MIRU typing may nevertheless serve as a
first step in surveillance of potential transmission hotspots in a population, but further investi-
gations using whole genome sequencing (WGS) are required to provide additional resolution
[16]. As shown by other studies, WGS is able to discriminate between TB isolates at the single
nucleotide level (SNP) which can in turn identify TB cases which are most likely to linked by
transmission [35, 36]. This genotyping technique has improved understanding of the TB epi-
demic in other Southern African countries.
Thirdly, there are other variables than those analyzed that could have played a role in the
dominance and distribution of M.tb lineages; these include the frequency of social gatherings,
family history of TB and travel history that were not investigated in this study. Finally, we did
not have treatment outcome data for the patients and could therefore not determine if there is
any association between treatment outcomes and M.tb lineage. Despite these limitations, our
study provides important baseline information on the circulating M.tb strains and on the types
of M.tb drug resistance present in Botswana. Such data is invaluable for the planning of future
studies investigating the molecular epidemiology of M.tb and its transmission dynamics.
Conclusions
Our study provides baseline data on the genetic diversity of M.tb strains circulating in
Botswana which could be used for future molecular epidemiology studies and contributes to
the body of knowledge regarding global M.tb genetic diversity. It also shows the utility of spoli-
gotyping and 12 loci MIRU in robustly assigning lineages and understanding the M.tb popula-
tion structure in a TB endemic setting. However, there is a need for further epidemiological
studies over extended period of time using whole genome sequencing to determine the precise
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genetic diversity and the transmission dynamics of M.tb strains in Botswana using a sample set
that is representative of the entire country.
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